Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.
- Singapore patent granted for ISLA-101 antiviral use
- Protection extends to Dengue and Chikungunya viruses
- Patent valid until April 2034 for commercial exclusivity
- Enhances Island’s positioning in Asia-Pacific region
- Supports clinical development and future partnering
Singapore Patent Boosts ISLA-101’s Market Exclusivity
Island Pharmaceuticals (ASX:ILA) has secured a pivotal patent from the Intellectual Property Office of Singapore, protecting its antiviral candidate ISLA-101 for the treatment of flavivirus infections, notably Dengue and Chikungunya viruses. This patent, valid until 16 April 2034, fortifies Island’s intellectual property estate and underpins the company’s long-term commercial exclusivity in a strategically vital Asia-Pacific market where these mosquito-borne diseases remain endemic.
Broadening Protection Beyond Dengue
The newly granted patent covers ISLA-101’s use as a standalone antiviral therapy against flaviviruses, explicitly including Chikungunya, a disease with significant global health impact and no widely available antiviral treatment. This expansion beyond Dengue reflects Island’s strategy to maximise ISLA-101’s potential across multiple viral indications, enhancing its appeal to partners and investors as it progresses through clinical development.
Strategic Importance of Singapore and Asia-Pacific
Singapore’s role as a key jurisdiction in the Asia-Pacific region adds weight to this patent grant. The region continues to face a substantial public health burden from mosquito-borne viruses, making patent protection here critical for Island’s commercial and partnering ambitions. This move complements the company’s broader intellectual property strategy aimed at securing exclusivity in territories with high disease prevalence and commercial relevance.
Advancing Clinical Development and Partnering Prospects
Island’s CEO Dr David Foster highlighted the significance of the patent in enhancing ISLA-101’s exclusivity and supporting future commercial opportunities across Asia. As the company advances ISLA-101 through clinical trials, maintaining and expanding its patent portfolio remains central to maximising the program’s long-term value. This development comes on the back of encouraging Phase 2a trial data demonstrating ISLA-101’s safety and antiviral activity against Dengue, underscoring the program’s clinical promise.
Positioning Within a Dual Antiviral Strategy
Island’s antiviral pipeline also includes Galidesivir, a broad-spectrum antiviral targeting over 20 RNA viruses with biodefence and outbreak response applications. While Galidesivir advances under regulatory pathways including the US FDA’s Animal Rule, the ISLA-101 patent grant strengthens Island’s focused approach on flavivirus diseases with high unmet medical need in endemic regions.
Bottom Line?
Island’s Singapore patent solidifies ISLA-101’s commercial moat in a critical market, but clinical progress and partnering deals will be key to unlocking its full value.
Questions in the middle?
- How will Island leverage this patent in upcoming ISLA-101 partnering negotiations?
- What are the timelines and milestones for ISLA-101’s next clinical phases in Asia-Pacific?
- Could extending protection to Chikungunya open new markets or regulatory pathways for Island?